Galectins as pivotal components in oncogenesis and immune exclusion in human malignancies
Galectins are galactoside-binding proteins, exerting numerous functions inside and outside the cell, particularly conferring adaptation to stress factors. For most of them, aberrant expression profiles have been reported in the context of cancer. Albeit not being oncogenic drivers, galectins can be...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-02-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1145268/full |
| _version_ | 1811173343285477376 |
|---|---|
| author | Nikiforos-Ioannis Kapetanakis Pierre Busson |
| author_facet | Nikiforos-Ioannis Kapetanakis Pierre Busson |
| author_sort | Nikiforos-Ioannis Kapetanakis |
| collection | DOAJ |
| description | Galectins are galactoside-binding proteins, exerting numerous functions inside and outside the cell, particularly conferring adaptation to stress factors. For most of them, aberrant expression profiles have been reported in the context of cancer. Albeit not being oncogenic drivers, galectins can be harnessed to exacerbate the malignant phenotype. Their impact on disease establishment and progression is not limited to making cancer cells resistant to apoptosis, but is prominent in the context of the tumor microenvironment, where it fosters angiogenesis, immune escape and exclusion. This review focuses mainly on Gal-1, Gal-3 and Gal-9 for which the involvement in cancer biology is best known. It presents the types of galectin dysregulations, attempts to explain the mechanisms behind them and analyzes the different ways in which they favor tumour growth. In an era where tumour resistance to immunotherapy appears as a major challenge, we highlight the crucial immunosuppressive roles of galectins and the potential therapeutic benefits of combinatorial approaches including galectin inhibition. |
| first_indexed | 2024-04-10T17:46:23Z |
| format | Article |
| id | doaj.art-61eaeb9d9bcb4e1d9fa694458472db10 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-10T17:46:23Z |
| publishDate | 2023-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-61eaeb9d9bcb4e1d9fa694458472db102023-02-03T04:59:12ZengFrontiers Media S.A.Frontiers in Immunology1664-32242023-02-011410.3389/fimmu.2023.11452681145268Galectins as pivotal components in oncogenesis and immune exclusion in human malignanciesNikiforos-Ioannis Kapetanakis0Pierre Busson1Research & Development (R&D), 4D Lifetec, Cham, SwitzerlandHost-Tumor Interactions in Head and Neck Carcinoma: Exploration and Therapeutic Modulations, Centre National de la Recherche Scientifique (CNRS), Unité Mixte de Recherche(UMR) 9018 - METabolic and SYstemic aspects of oncogenesis for new therapeutic approaches (METSY), Gustave Roussy and Université Paris-Saclay, Villejuif, FranceGalectins are galactoside-binding proteins, exerting numerous functions inside and outside the cell, particularly conferring adaptation to stress factors. For most of them, aberrant expression profiles have been reported in the context of cancer. Albeit not being oncogenic drivers, galectins can be harnessed to exacerbate the malignant phenotype. Their impact on disease establishment and progression is not limited to making cancer cells resistant to apoptosis, but is prominent in the context of the tumor microenvironment, where it fosters angiogenesis, immune escape and exclusion. This review focuses mainly on Gal-1, Gal-3 and Gal-9 for which the involvement in cancer biology is best known. It presents the types of galectin dysregulations, attempts to explain the mechanisms behind them and analyzes the different ways in which they favor tumour growth. In an era where tumour resistance to immunotherapy appears as a major challenge, we highlight the crucial immunosuppressive roles of galectins and the potential therapeutic benefits of combinatorial approaches including galectin inhibition.https://www.frontiersin.org/articles/10.3389/fimmu.2023.1145268/fullgalectinscancerimmune evasiontumor microenvironmentgalectin inhibitorscombination immunotherapy |
| spellingShingle | Nikiforos-Ioannis Kapetanakis Pierre Busson Galectins as pivotal components in oncogenesis and immune exclusion in human malignancies Frontiers in Immunology galectins cancer immune evasion tumor microenvironment galectin inhibitors combination immunotherapy |
| title | Galectins as pivotal components in oncogenesis and immune exclusion in human malignancies |
| title_full | Galectins as pivotal components in oncogenesis and immune exclusion in human malignancies |
| title_fullStr | Galectins as pivotal components in oncogenesis and immune exclusion in human malignancies |
| title_full_unstemmed | Galectins as pivotal components in oncogenesis and immune exclusion in human malignancies |
| title_short | Galectins as pivotal components in oncogenesis and immune exclusion in human malignancies |
| title_sort | galectins as pivotal components in oncogenesis and immune exclusion in human malignancies |
| topic | galectins cancer immune evasion tumor microenvironment galectin inhibitors combination immunotherapy |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1145268/full |
| work_keys_str_mv | AT nikiforosioanniskapetanakis galectinsaspivotalcomponentsinoncogenesisandimmuneexclusioninhumanmalignancies AT pierrebusson galectinsaspivotalcomponentsinoncogenesisandimmuneexclusioninhumanmalignancies |